CLONICEL (Clonidine Sustained Release) as Add-on to Stimulant Medication in 6 to 17 Yr-olds With ADHD
Phase III Evaluation of the Safety and Efficacy of CLONICEL (Clonidine HCl Sustained Release) as Add-on to Psychostimulant Medication vs. Psychostimulant Medication Alone in Children and Adolescents With ADHD
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
-
-
California
-
El Centro, California, United States, 92243
-
Irvine, California, United States, 92612
-
San Diego, California, United States, 92103
-
-
Florida
-
Bradenton, Florida, United States, 34208
-
Lauderhill, Florida, United States, 33319
-
Miami, Florida, United States, 33161
-
-
Kentucky
-
Bardstown, Kentucky, United States, 40004
-
-
Maryland
-
Baltimore, Maryland, United States, 21208
-
-
Missouri
-
St. Louis, Missouri, United States, 63005
-
-
New Jersey
-
Clementon, New Jersey, United States, 08021
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
-
Durham, North Carolina, United States, 27705
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73103
-
Oklahoma City, Oklahoma, United States, 73116
-
-
Texas
-
Houston, Texas, United States, 77007
-
Houston, Texas, United States, 77074
-
Lake Jackson, Texas, United States, 77566
-
Wharton, Texas, United States, 77488
-
-
Utah
-
Clinton, Utah, United States, 84015
-
-
Washington
-
Kirkland, Washington, United States, 98033
-
Spokane, Washington, United States, 99202
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 6-17 years, inclusive
- Diagnosis of ADHD
- Currently on a stable psychostimulant regimen for ADHD
- Lack of adequate response to stable psychostimulant regimen
- Ability to swallow tablets
Exclusion Criteria:
- Clinically significant illnesses or abnormalities upon evaluation
- Conduct Disorder
- Intolerance to clonidine
- History of seizures or syncope
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
|
Flexible Dose (0.1 - 0.4 mg)
|
|
Placebo Comparator: 2
|
Matching placebo tablets
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
ADHDRS-IV Total Score
Time Frame: Week 5
|
Week 5
|
|
Treatment Emergent Adverse Events, Laboratory Tests, Vital Signs, and ECGs
Time Frame: Throughout Treatment and Follow-up Period
|
Throughout Treatment and Follow-up Period
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Moise Khayrallah, PhD, Addrenex Pharmaceuticals
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Sympatholytics
- Clonidine
Other Study ID Numbers
Other Study ID Numbers
- CLON-302
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.